Issues
-
Cover Image
Cover Image
The surge of colorectal cancer (CRC) in young adults has been attributed to environmental exposures, such as changes in lifestyle, which, in part, act via alterations in the gut microbiome. In this study starting on page 29, Adnan and colleagues found age-related differences in the CRC-associated gut microbiome by analyzing data from several hundred CRC and healthy individuals. Their analysis unraveled distinct microbial-host interactions at the tumor site of early-onset vs. late-onset CRCs. Overall, findings from this study lend support to an age-dependent role of intestinal microbes in colon tumorigenesis. The cover image is adapted from Fig. 1 that exhibits fecal microbiome compositions and differentially abundant species between CRC and control subjects. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Commentaries
Research Articles
Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
This study of intrafamilial communication and cascade genetic testing experiences of patients with hereditary cancer and their relatives from diverse, medically underserved populations identified relatives’ perceived susceptibility to hereditary cancer risks, distress, and fear as frequent reactions and barriers to testing. These results may inform future hereditary cancer prevention efforts.
Early-onset Colon Cancer Shows a Distinct Intestinal Microbiome and a Host–Microbe Interaction
Early-onset colorectal cancer is on the rise, presumably because of changes in environmental exposures. Lifestyle changes may contribute to colorectal cancer via alterations in gut microbes. Here, we show that microbial association with colorectal cancer is age-dependent, and microbe interactions with tumor pathways are stronger in young versus older colorectal cancers.
Acknowledgment to Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.